D Deandreis
Overview
Explore the profile of D Deandreis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
431
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hadoux J, Lamarca A, Grande E, Deandreis D, Kaltsas G, Janson E, et al.
ESMO Open
. 2024 Oct;
9(10):103664.
PMID: 39461777
No abstract available.
2.
Nervo A, Ragni A, Retta F, Gallo M, Piovesan A, Liberini V, et al.
J Endocrinol Invest
. 2020 Aug;
44(3):403-419.
PMID: 32743746
Bone represents the second most common site of distant metastases in differentiated thyroid cancer (DTC). The clinical course of DTC patients with bone metastases (BM) is quite heterogeneous, but generally...
3.
Dromain C, Deandreis D, Scoazec J, Goere D, Ducreux M, Baudin E, et al.
Diagn Interv Imaging
. 2016 Nov;
97(12):1241-1257.
PMID: 27876341
Pancreatic neuroendocrine tumors (PNETs) are rare and represent a heterogeneous disease. PNET can be functioning or non-functioning with different clinical presentations and different prognosis based on WHO and pTNM classifications....
4.
Lamartina L, Ippolito S, Danis M, Bidault F, Borget I, Berdelou A, et al.
J Clin Endocrinol Metab
. 2016 Apr;
101(7):2733-41.
PMID: 27082933
Background: Antiangiogenic tyrosine kinase inhibitors (TKIs) are the mainstay of advanced thyroid cancer (TC) treatment. Concern is rising about TKI-related toxicity. Objective: To determine the incidence and to investigate the...
5.
Hadoux J, Malka D, Planchard D, Scoazec J, Caramella C, Guigay J, et al.
Endocr Relat Cancer
. 2015 Mar;
22(3):289-98.
PMID: 25770151
There is no standard for second-line chemotherapy in poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC) patients. We analyzed the antitumor efficacy of 5-fluorouracil and oxaliplatin (FOLFOX) chemotherapy in this population....
6.
Deutsch E, Le Pechoux C, Faivre L, Rivera S, Tao Y, Pignon J, et al.
Ann Oncol
. 2015 Feb;
26(6):1223-1229.
PMID: 25701455
Background: This phase I study evaluated the safety and efficacy of the oral mTOR inhibitor everolimus in combination with thoracic radiotherapy followed by consolidation chemotherapy in locally advanced or oligometastatic...
7.
Lepoutre-Lussey C, Caramella C, Bidault F, Deandreis D, Berdelou A, Al Ghuzlan A, et al.
Eur J Nucl Med Mol Imaging
. 2015 Feb;
42(6):868-76.
PMID: 25676472
Purpose: Specific recommendations on screening modalities for paraganglioma (PGL) and phaeochromocytoma (PCC) in asymptomatic SDHx mutation carriers (relatives) are still lacking. We evaluated the added value of (18)F-FDG PET/CT in...
8.
Nascimento C, Borget I, Troalen F, Al Ghuzlan A, Deandreis D, Hartl D, et al.
Eur J Endocrinol
. 2013 Aug;
169(5):689-93.
PMID: 23939918
Context: Thyroglobulin (Tg) measurement is a major tool for the follow-up of differentiated thyroid cancer (DTC) patients; however, in patients who do not undergo radioactive iodine (RAI) ablation, normal ultrasensitive...
9.
Baudin E, Leboulleux S, Al Ghuzlan A, Chougnet C, Young J, Deandreis D, et al.
Horm Cancer
. 2011 Dec;
2(6):363-71.
PMID: 22161625
The prognosis of advanced adrenocortical carcinoma (ACC) is dismal but heterogeneous. In 2011, mitotane is the only drug approved in Europe and US for the treatment of advanced ACC. Mitotane...
10.
Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Chami L, Travagli J, et al.
Endocr Relat Cancer
. 2010 Dec;
18(2):R29-40.
PMID: 21183629
(131)I is given in differentiated thyroid cancer (DTC) without taking into account thyroglobulin (Tg) levels at the time of ablation, whereas 6-18 months later it is a major criterion for...